Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
Objective: The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the opt...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594118296993792 |
|---|---|
| author | Yichen Dong, MD Long Xu, MD Jialiang Wen, MD Haojie Si, MD Juemin Yu, MD Tao Chen, MD Huikang Xie, MD Xinjian Li, MD Minglei Yang, MD Junqiang Fan, MD Junqi Wu, MD Yunlang She, MD Deping Zhao, MD Chang Chen, MD, PhD |
| author_facet | Yichen Dong, MD Long Xu, MD Jialiang Wen, MD Haojie Si, MD Juemin Yu, MD Tao Chen, MD Huikang Xie, MD Xinjian Li, MD Minglei Yang, MD Junqiang Fan, MD Junqi Wu, MD Yunlang She, MD Deping Zhao, MD Chang Chen, MD, PhD |
| author_sort | Yichen Dong, MD |
| collection | DOAJ |
| description | Objective: The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the optimal number of cycles. Methods: A total of 438 patients who received neoadjuvant chemoimmunotherapy between August 2019 and June 2022 across four hospitals were enrolled in this study, with a median follow-up time of 31.3 months. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods and tested by log-rank test. Unstratified Cox proportional hazards models were fitted to the subgroups. Results: In this multi-center cohort, 29.7% of patients (n = 130) achieved a pathologic complete response. Patients who received adjuvant immunotherapy experienced significant survival benefits compared with those who did not (RFS: hazard ratio [HR] = 0.63, 95% confidence interval: 0.41–0.98, p = 0.037; OS: hazard ratio = 0.27, 95% confidence interval: 0.13–0.57, p < 0.001). Subgroup analyses found that patients with a squamous histologic type, positive PD-L1 expression, and those with a major pathologic response particularly benefited from adjuvant immunotherapy. In addition, we found that six cycles of adjuvant immunotherapy served as a threshold for better prognostic differentiation, suggesting that six or more cycles may be more beneficial. Conclusions: Our study found that the addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy is significantly associated with improved RFS and OS in patients with resectable NSCLC. We also identified that six cycles of adjuvant immunotherapy may be the optimal regimen for these patients. |
| format | Article |
| id | doaj-art-0abd056787f74db8a12f0c36449ac977 |
| institution | Kabale University |
| issn | 2666-3643 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-0abd056787f74db8a12f0c36449ac9772025-01-20T04:17:55ZengElsevierJTO Clinical and Research Reports2666-36432025-01-0161100763Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief ReportYichen Dong, MD0Long Xu, MD1Jialiang Wen, MD2Haojie Si, MD3Juemin Yu, MD4Tao Chen, MD5Huikang Xie, MD6Xinjian Li, MD7Minglei Yang, MD8Junqiang Fan, MD9Junqi Wu, MD10Yunlang She, MD11Deping Zhao, MD12Chang Chen, MD, PhD13Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Ningbo Hospital, Zhejiang University, Ningbo, People's Republic of ChinaDepartment of Thoracic Surgery, Ningbo Number 2 Hospital, Chinese Academy of Sciences, Zhejiang, People's Republic of ChinaDepartment of Thoracic Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China; Corresponding author. Address for correspondence: Chang Chen, MD, PhD, Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Zhengmin Road, Shanghai 200443, People's Republic of China.Objective: The potential survival benefits of adjuvant immunotherapy for resectable NSCLC after neoadjuvant chemoimmunotherapy, and the optimal number of adjuvant immunotherapy cycles, remain uncertain. This study aims to evaluate the prognostic impact of adjuvant immunotherapy and determine the optimal number of cycles. Methods: A total of 438 patients who received neoadjuvant chemoimmunotherapy between August 2019 and June 2022 across four hospitals were enrolled in this study, with a median follow-up time of 31.3 months. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods and tested by log-rank test. Unstratified Cox proportional hazards models were fitted to the subgroups. Results: In this multi-center cohort, 29.7% of patients (n = 130) achieved a pathologic complete response. Patients who received adjuvant immunotherapy experienced significant survival benefits compared with those who did not (RFS: hazard ratio [HR] = 0.63, 95% confidence interval: 0.41–0.98, p = 0.037; OS: hazard ratio = 0.27, 95% confidence interval: 0.13–0.57, p < 0.001). Subgroup analyses found that patients with a squamous histologic type, positive PD-L1 expression, and those with a major pathologic response particularly benefited from adjuvant immunotherapy. In addition, we found that six cycles of adjuvant immunotherapy served as a threshold for better prognostic differentiation, suggesting that six or more cycles may be more beneficial. Conclusions: Our study found that the addition of adjuvant immunotherapy to neoadjuvant chemoimmunotherapy is significantly associated with improved RFS and OS in patients with resectable NSCLC. We also identified that six cycles of adjuvant immunotherapy may be the optimal regimen for these patients.http://www.sciencedirect.com/science/article/pii/S2666364324001334Non-small cell lung cancerNeoadjuvant chemoimmunotherapyAdjuvant immunotherapyPerioperative immunotherapy |
| spellingShingle | Yichen Dong, MD Long Xu, MD Jialiang Wen, MD Haojie Si, MD Juemin Yu, MD Tao Chen, MD Huikang Xie, MD Xinjian Li, MD Minglei Yang, MD Junqiang Fan, MD Junqi Wu, MD Yunlang She, MD Deping Zhao, MD Chang Chen, MD, PhD Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report JTO Clinical and Research Reports Non-small cell lung cancer Neoadjuvant chemoimmunotherapy Adjuvant immunotherapy Perioperative immunotherapy |
| title | Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report |
| title_full | Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report |
| title_fullStr | Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report |
| title_full_unstemmed | Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report |
| title_short | Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report |
| title_sort | prognostic impact of adjuvant immunotherapy in patients with resectable nsclc after neoadjuvant chemoimmunotherapy a brief report |
| topic | Non-small cell lung cancer Neoadjuvant chemoimmunotherapy Adjuvant immunotherapy Perioperative immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324001334 |
| work_keys_str_mv | AT yichendongmd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT longxumd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT jialiangwenmd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT haojiesimd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT jueminyumd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT taochenmd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT huikangxiemd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT xinjianlimd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT mingleiyangmd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT junqiangfanmd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT junqiwumd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT yunlangshemd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT depingzhaomd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport AT changchenmdphd prognosticimpactofadjuvantimmunotherapyinpatientswithresectablensclcafterneoadjuvantchemoimmunotherapyabriefreport |